Evidence map›Paper›PMID 41463041›Full record

ArticleBiomedicines2025

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Risako Suzuki, Ryotaro Ohkuma, Makoto Watanabe, Emiko Mura, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Go Ikeda, Masahiro Shimokawa and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Risako SuzukiDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Ryotaro OhkumaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Makoto WatanabeDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.
Emiko MuraDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Toshiaki TsuruiDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Nana IriguchiDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Tomoyuki IshiguroDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Yuya HirasawaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Go IkedaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.ORCID 0009-0006-7333-7095
Masahiro ShimokawaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.ORCID 0000-0002-8645-4112
Hirotsugu AriizumiDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Yutaro KubotaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Kiyoshi YoshimuraDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.
Shinichi KobayashiClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.
Takuya TsunodaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.ORCID 0000-0002-6416-8211
Atsushi HoriikeDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.ORCID 0000-0001-6941-7494
Mayumi TsujiPharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.ORCID 0000-0001-8005-9069
Yuji KiuchiDepartment of Pharmacology, Showa Medical University Graduate School of Medicine, Tokyo 142-8555, Japan.
Tatsunori OguchiDepartment of Pharmacology, Showa Medical University Graduate School of Medicine, Tokyo 142-8555, Japan.
Satoshi WadaDepartment of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8666, Japan.ORCID 0000-0001-6528-5914

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkereosinophilimmune checkpoint inhibitorNLRoverall survivalprogression-free survivalretrospective study

Identifiers

PMID41463041
PMCPMC12730934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.